The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies

Filter

Type

Issue

This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). It shows how these companies are using the patent system as a key tool to maximize revenues, profitability, and shareholder returns. Through the creation of patent thickets,…

Briefs & Reports 17 Apr 2025

Biologics, Biosimilars and Patents: A Beginner’s Guide

Given the recent history of the BPCIA and the ongoing understanding of how the regulatory aspects are working in practice, including the multiple types of biologic products that are covered by the law, it can seem quite a complicated system for those not in the business. It is with this in mind that we created…

Briefs & Reports 13 May 2024

I-MAK & AELP: The Costs of Pharma Cheating

Briefs & Reports 23 Jun 2023

ITC Testimony

Submissions 21 Mar 2023

Request for Comments on USPTO Initiatives to Ensure the Robustness and Reliability of Patent Rights (USPTO Docket No. PTO-P-2022-0025)

Submissions 21 Feb 2023

Public Comment Joint USPTO-FDA Collaboration Initiatives; Notice of Public Listening Session

Submissions 21 Feb 2023

Supplemental Comments on the Joint USPTO-FDA Collaboration Initiatives Listening Session

Submissions 21 Feb 2023

Drug Patent Book